A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..
NCT ID: NCT01200524
Last Updated: 2014-04-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
133 participants
INTERVENTIONAL
2010-10-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
NCT01201317
Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain
NCT00976534
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
NCT00939094
Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain
NCT01752322
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
NCT00120120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD2423, 20mg
AZD2423
20 mg tablet
AZD2423, 150 mg
AZD2423
50 mg tablet
Placebo
Tablet to match the 20 mg and 50 mg AZD2423 active tablet
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD2423
20 mg tablet
AZD2423
50 mg tablet
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and female patients aged 18 to 80 years
* Patients with neuropathic pain due to peripheral nerve injury caused by trauma or surgery
Exclusion Criteria
* History of treatment failure with more than three adequate trials of treatment for neuropathic pain
* Central neuropathic pain conditions (caused by Central Nervous System injury/disease, eg. Stroke)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bror Jonzon
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Pleven, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Aalborg, , Denmark
Research Site
Odense, , Denmark
Research Site
Boulogne-Billancourt, , France
Research Site
Clermont-Ferrand, , France
Research Site
Nice, , France
Research Site
Saint-Priest-en-Jarez, , France
Research Site
Gdansk, , Poland
Research Site
Katowice, , Poland
Research Site
Krakow, , Poland
Research Site
Poznan, , Poland
Research Site
Tychy, , Poland
Research Site
Warsaw, , Poland
Research Site
Kazan', , Russia
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Ufa, , Russia
Research Site
Falköping, , Sweden
Research Site
Kristianstad, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Birmingham, , United Kingdom
Research Site
Bradford, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2600C00012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.